Short Interest in Alterity Therapeutics Limited (NASDAQ:ATHE) Grows By 290.9%

Alterity Therapeutics Limited (NASDAQ:ATHE) saw a large increase in short interest in April. As of April 15th, there was short interest totalling 90,300 shares, an increase of 290.9% from the March 31st total of 23,100 shares. Currently, 1.1% of the shares of the stock are sold short. Based on an average daily trading volume, of 82,300 shares, the days-to-cover ratio is currently 1.1 days.

Analysts Set New Price Targets

Separately, Benchmark reiterated a “speculative buy” rating and set a $4.00 target price on shares of Alterity Therapeutics in a research report on Thursday, March 7th.

Alterity Therapeutics Price Performance

Shares of NASDAQ:ATHE traded down $0.07 during midday trading on Thursday, reaching $2.26. 24,573 shares of the company were exchanged, compared to its average volume of 77,546. The business’s fifty day moving average is $1.95 and its two-hundred day moving average is $2.18. Alterity Therapeutics has a one year low of $1.55 and a one year high of $5.41.

About Alterity Therapeutics

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease.